Basel-based biotech startup NUCLIDIUM, which develops copper-based radiopharmaceuticals for cancer diagnosis and treatment, has raised €84 million in a Series B funding round.
- Founded in 2017 by Leila Jaafar, NUCLIDIUM is a clinical-stage biotech company with offices in Basel and Munich, developing copper-based radiopharmaceuticals aimed at improving cancer diagnosis and treatment.
- Its platform pairs Copper-61 for imaging with Copper-67 for therapy, both linked to tumor-targeting molecules, enabling a theranostic approach that combines diagnostics and treatment in a single molecular structure.
- This method is designed to enhance clinical precision while simplifying care delivery. NUCLIDIUM’s lead compounds, NuriPro™ and TraceNET™, are currently in clinical development for a range of cancers, including metastatic prostate cancer, neuroendocrine tumors, and breast cancer.
“ Our groundbreaking next generation copper theranostic platform also allows us to rapidly develop new targets across a wider range of cancers, particularly those highly relevant to women’s health," claims Leila Jaafar, PhD, CEO and co-founder of NUCLIDIUM,
Details of the deal
- The Series B round was led by Kurma Growth Opportunities Fund (Kurma Partners), Angelini Ventures (Angelini Industries), Wellington Partners, and Neva SGR (Intesa Sanpaolo Group).
- The investemnt also saw participation from DeepTech & Climate Fonds (DTCF), Bayern Kapital, Vives Partners, Eurazeo, NRW.BANK, HighLight Capital, and existing investors.
“This investment reflects our strong conviction in the future of precision medicine and our belief in NUCLIDIUM’s potential to scale as a next-generation company, an ambition shared across a strong European syndicate,” claims Daniel Parera, MD, Partner at Kurma Partners, Regina Hodits, PhD, Managing Director at Angelini Ventures, and Liliana Nordbakk, Partner Life Sciences at Neva SGR for all participating investors.
- The company plans to expand its global production and manufacturing network to support clinical supply and future commercialization.
- Additionally, NUCLIDIUM will grow its international team and strengthen collaborations with hospitals and academic centers in Europe and North America to accelerate research and development efforts.
